

Convention: SC		Assessment of continued need for lindane
LEGAL BASIS/MANDATE:		
<ul style="list-style-type: none"> PoW 22 (SC) Scientific support to Parties of the Stockholm Convention Related COP decision: SC-6/2: Exemptions 		
BACKGROUND INFORMATION:		
<p>By decision SC 4/15 the Conference of the Parties to the Stockholm Convention (COP) listed lindane under Annex A of the Convention and requested for the Secretariat to cooperate with the World Health Organization (WHO) in developing reporting and reviewing requirements for the use of lindane as a human health pharmaceutical for the control of head lice and scabies, taking into consideration the concluding statement in the Persistent Organic Pollutants Review Committee's risk management evaluation on lindane. Accordingly activities were undertaken¹ including a study of health sector information sources and WHO databases. The results reveal that lindane is still marketed in countries as a pharmaceutical for head lice and scabies. Furthermore, of the 99 national essential medicines lists examined, 24 list lindane as essential medicine for the treatment of head lice and scabies (UNEP/POPS/COP.6/INF/4). The Secretariat also conducted a series of webinars enabling parties to share information and experiences on introducing alternatives to lindane and facilitating the Secretariat's development of activities to support parties in reviewing the continued need for lindane.</p> <p>By the decision SC-6/2 the COP requested the Secretariat, to continue to take the lead in implementing the activities on reporting and reviewing requirements for the use of lindane as a human health pharmaceutical, and to report to the Conference of the Parties at its seventh meeting on the progress of those activities. Based on the information gathered through the above activities, a draft framework for reporting and reviewing of lindane needs to be developed and undertake an initial assessment of information through an expert consultation for consideration by the Conference of the Parties at its seventh meeting. The outcomes of expert consultation should form a basis for the development of training material to enhance capacity for parties to regulate lindane and to introduce alternatives.</p>		
PROPOSED ACTIVITIES TO BE FUNDED:		
<ol style="list-style-type: none"> A consultant to prepare a preliminary report on a review of information related to accessibility to lindane and its alternatives and a draft framework for the assessment of lindane. A meeting of an expert panel: <ul style="list-style-type: none"> to establish requirements for the assessment of continued need for lindane and to facilitate introducing alternatives; and to prepare a report to the COP on an assessment of information on lindane and its alternatives for its consideration for continued need for lindane. 		
RESULTS TO BE ACHIEVED:		
<ul style="list-style-type: none"> A framework including requirements for reporting and reviewing of lindane as a pharmaceutical; A report on an assessment of information on lindane and its alternatives as a pharmaceutical for the consideration of the COP at its seventh meeting; Information to facilitate Parties on the evaluation and introduction of alternatives to lindane. 		
VOLUNTARY BUDGET [USD] FOR 2014-2015		
10	PROJECT PERSONNEL COMPONENT	
1100	P-3 Programme Officer post	55,500
1200	Consultants	10,000

¹ UNEP/POPS/COP.5/18.

VOLUNTARY BUDGET [USD] FOR 2014-2015		
30	TRAINING COMPONENT	
3300	<i>Meetings and Conferences²</i>	20,000
	DIRECT PROJECT COST OPERATIONAL BUDGET	85,500
	Programme Support Costs (PSC) 13%	11,115
	TOTAL OPERATIONAL BUDGET	96,615

² USD 16,000 for the implementation of 2 workshop modules (USD 8,000* each) to enhance capacity for parties to regulate lindane and to introduce alternatives are budgeted under PoW 16(SC)